Format

Send to

Choose Destination
Diabetes Care. 2017 Feb;40(2):164-170. doi: 10.2337/dc15-2780. Epub 2016 Sep 14.

Pancreatic Safety of Sitagliptin in the TECOS Study.

Author information

1
University of North Carolina School of Medicine, Chapel Hill, NC jbuse@med.unc.edu.
2
Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, U.K.
3
Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
4
Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia.
5
Centre Region CINVEC, Viña del Mar, Chile.
6
University Specialized Hospital for Active Treatment in Endocrinology, Medical University, Sofia, Bulgaria.
7
E. Wolfson Medical Center, Holon, Israel.
8
St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
9
The George Washington University Biostatistics Center, Rockville, MD.
10
Merck & Co., Inc., Kenilworth, NJ.
11
Toronto Centre for Liver Disease, Division of Gastroenterology, University of Toronto Health Network, Toronto, Ontario, Canada.

Abstract

OBJECTIVE:

We evaluated the incidence of acute pancreatitis and pancreatic cancer in patients with type 2 diabetes and cardiovascular disease who were treated with sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i).

RESEARCH DESIGN AND METHODS:

In the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) study, a cardiovascular safety study of sitagliptin, all suspected cases of acute pancreatitis and pancreatic cancer were collected prospectively for 14,671 participants during a median follow-up time of 3 years, and were adjudicated blindly.

RESULTS:

Baseline differences were minimal between participants confirmed to have no pancreatic events, acute pancreatitis, or pancreatic cancer. Among those participants randomized to receive sitagliptin, 23 (0.3%) (vs. 12 randomized to receive placebo [0.2%]) had pancreatitis (hazard ratio 1.93 [95% CI 0.96-3.88], P = 0.065; 0.107 vs. 0.056/100 patient-years), with 25 versus 17 events, respectively. Severe pancreatitis (two fatal) occurred in four individuals allocated to receive sitagliptin. Cases of pancreatic cancer were numerically fewer with sitagliptin (9 [0.1%]) versus placebo (14 [0.2%]) (hazard ratio 0.66 [95% CI 0.28-1.51], P = 0.32; 0.042 vs. 0.066 events/100 patient-years). Meta-analysis with two other DPP-4i cardiovascular outcome studies showed an increased risk for acute pancreatitis (risk ratio 1.78 [95% CI 1.13-2.81], P = 0.01) and no significant effect for pancreatic cancer (risk ratio 0.54 [95% CI 0.28-1.04], P = 0.07).

CONCLUSIONS:

Pancreatitis and pancreatic cancer were uncommon events with rates that were not statistically significantly different between the sitagliptin and placebo groups, although numerically more sitagliptin participants developed pancreatitis and fewer developed pancreatic cancer. Meta-analysis suggests a small absolute increased risk for pancreatitis with DPP-4i therapy.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00790205.

PMID:
27630212
PMCID:
PMC5864139
DOI:
10.2337/dc15-2780
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center